NCT03555851View on ClinicalTrials.gov

Factors Affecting Post-transplant Cyclophosphamide (PTCy) Efficacy

RecruitingOBSERVATIONAL
Enrollment

120

Participants

Timeline

Start Date

July 13, 2018

Primary Completion Date

October 31, 2033

Study Completion Date

August 31, 2035

Conditions
Leukemia, Not Otherwise SpecifiedLeukemia, Other
Interventions
DRUG

Cyclophosphamide

Pharmacogenomics of candidate genes and pharmacokinetic analyses of cyclophosphamide administered as part of a reduced intensity conditioning (RIC) regimen and as post-transplant GVHD prophylaxis will be examined.

OTHER

Specimen collection

Buccal swabs will be obtained from donors for pharmacogenomics.

Trial Locations (1)

28204

RECRUITING

Levine Cancer Institute, Charlotte

All Listed Sponsors
collaborator

Atrium Health Levine Cancer Institute

OTHER

lead

Wake Forest University Health Sciences

OTHER